Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

Primary Objective: To assess the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination

  • 0 views
  • 19 Jul, 2021
  • 11 locations
Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.

This research is a multi-center French randomized and double blind phase IIb clinical trial evaluating 2 revaccination strategies against pneumococcal infections among splenectomised patients. The main objective is to evaluate at M13 the immunological response of 2 pneumococcal revaccination strategies (combined revaccination by a boost dose of PCV13 following 12 …

  • 0 views
  • 17 Sep, 2021
  • 2 locations
Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab

vaccine (Pneumovax). For their utilization, several studies approved a prime-boost strategy. It consist two administer Pneumovax at least two months later than Prevenar. Patients with diffuse large B-cell

immunosuppression
anti-cd20 monoclonal antibody
r-chop
diffuse large b-cell lymphoma
polysaccharide
  • 0 views
  • 27 May, 2021
  • 1 location
Vaccine Response in Patient With Sepsis

), a conjugate vaccine recommended as a prime-boost since 2013, which must be followed by a vaccination at 2 months with Pneumovax, an unconjugated vaccine of 23 valences. Anti-pneumococcal

pneumococcal
pneumonia
bacteremia
  • 0 views
  • 13 Jun, 2021
  • 1 location